DCL0022 · Research use only
FS01 · Instructions for Use
For trained laboratory personnel conducting research. Select the experimental design using the original publication and your institutional procedures.
| Product | Information |
|---|---|
| Name / catalog | FS01 / DCL0022 |
| Formula | C53H91N3O6 |
| Molecular weight | 866.33 |
| Purity specification | >95% by ELSD-HPLC |
Before preparation
Check the supplied batch label, COA and approved SDS. Confirm supply format, solvent compatibility, storage and retest date with DC Chemicals.
Formulation reference
| Component | Catalog | Molecular weight | Molar proportion | Mass % |
|---|---|---|---|---|
| FS01 | DCL0022 | 866.33 | 50% | 62.00% |
| DSPC | DC57005 | 790.15 | 10% | 11.31% |
| Cholesterol | DCD-041 | 386.65 | 38.5% | 21.31% |
| DMG-PEG2000 | DC40169 | 2507 | 1.5% | 5.38% |
The Methods composition is shown. The Results component order conflicts with it; N/P is not reported. Resolve these source limitations before using the composition experimentally.
Stock-solution calculation
Required volume (mL) = mass (mg) × 1000 / [866.33 × concentration (mM)]. Calculation does not establish solubility.
| Mass | 10 mM volume | 20 mM volume |
|---|---|---|
| 10 mg | 1.1543 mL | 0.5771 mL |
| 25 mg | 2.8857 mL | 1.4429 mL |
| 50 mg | 5.7715 mL | 2.8857 mL |
| 100 mg | 11.5429 mL | 5.7715 mL |
| 250 mg | 28.8574 mL | 14.4287 mL |
Study interpretation
FS01 supports local mRNA-delivery research. Reported arthritis outcomes involve IL-1Ra and/or ANL3 mRNA formulations and do not establish an intrinsic therapeutic effect of the lipid.
Reference
Wang G, et al. Molecular Therapy (2026). DOI: 10.1016/j.ymthe.2026.10.021.